CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial tests a new virus-based drug (OBP-301) combined with standard chemotherapy and radiation for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and kill cancer cells. The main goal is to check…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before they have surgery. About 278 adults with stage II to IVA cancer will take part. The…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Immunotherapy combo shows promise for genetic stomach cancer subtype
Disease control OngoingThis study is for people with a certain type of stomach or gastroesophageal junction cancer that has a high number of genetic mutations (MSI-H/dMMR). It compares the immunotherapy drug atezolizumab alone versus atezolizumab combined with chemotherapy, given before and after surge…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug combo shows promise against esophageal cancer in early trial
Disease control OngoingThis early-phase trial is testing whether giving a mix of chemotherapy, radiation, an immunotherapy drug (pembrolizumab), and a targeted therapy (lenvatinib) before surgery can better kill esophageal cancer cells. The study includes about 3 adults with cancer that hasn't spread. …
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC